News - USA

Filter

Current filters:

USA

Popular Filters

1 to 25 of 596 results

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

25-07-2014

German drug major Bayer and Onyx Pharmaceuticals, an Amgen subsidiary (Nasdaq: AMGN), have said that…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

FDA approves Purdue’s abuse-deterrent opioid Targiniq ER for pain-management

FDA approves Purdue’s abuse-deterrent opioid Targiniq ER for pain-management

25-07-2014

The US Food and Drug Administration has approved privately-held USA-based Purdue Pharma’s abuse-deterrent…

AlcoholsAnalgesiaChemistryNaloxonePharmaceuticalPurdue PharmaRegulationTarginiqUSA

Sandoz application for biosimilar Neupogen accepted by US FDA

25-07-2014

The US Food and Drug Administration has accepted the Biologics License Application for filgrastim, which…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarzio

Hospira’s Retacrit effective in chemotherapy-induced anemia

Hospira’s Retacrit effective in chemotherapy-induced anemia

24-07-2014

USA-based Hospira, a leading provider of generic injectable drugs and infusion technologies, announced…

BiosimilarsErythropoiesis-stimulating agentsGenericsHematologyHospiraInfusion technologiesResearchRetacritUSA

Hikma to take over Boehringer’s Ben Venue manufacturing site

24-07-2014

Jordan-based drugmaker Hikma Pharmaceuticals says it has agreed with Ben Venue Laboratories, part of…

Ben Venue LabsBoehringer IngelheimGenericsHikma PharmaceuticalsMergers & AcquisitionsProductionUSA

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

24-07-2014

US biotech firm Biogen Idec said that the European Commission has approved its subcutaneous injectable…

Biogen IdecCytokinesMultiple sclerosisNeurologicalPharmaceuticalPlegridyRegulationUSA

US FDA approves Gilead’s Zydelig for three types of blood cancers

24-07-2014

The US Food and Drug Administration late yesterday approved Zydelig (idelalisib), a new drug from US…

BiotechnologyGilead SciencesidelalisibOncologyRegulationUSAZydelig

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

23-07-2014

Shares of US biotech firm Biogen Idec jumped 7.35% to $326 in pre-market trading today, as the company…

AlprolixBiogen IdecBiotechnologyElocateFinancialImmunologyPharmacologyTecfideraUSA

Shire in strategic collaboration with ArmaGen for Hunter syndrome

Shire in strategic collaboration with ArmaGen for Hunter syndrome

23-07-2014

Ireland-headquartered drugmaker Shire has entered into an agreement with US privately held biotech company…

AGT-182ArmagenBiotechnologyCNS DiseasesHunter syndromeIrelandLicensingShireUSA

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

23-07-2014

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours…

BiotechnologyLicensingneratinibOncologyPB272PfizerPuma BiotechResearchTrastuzumabUSA

Amgen’s evolocumab to become gold standard among add-on statin therapies

Amgen’s evolocumab to become gold standard among add-on statin therapies

22-07-2014

Leading independent biotech firm Amgen’s investigational compound evolocumab (AMG-145) is set to become…

AmgenBiotechnologyCardio-vascularCardiovascular diseaseEuropeevolocumabMarkets & MarketingUSA

Novasep sites approved by US FDA

Novasep sites approved by US FDA

22-07-2014

French active ngredients company Novasep has successfully completed US Food and Drug Administration pre-approval…

Active pharmaceutical ingredientFranceNovasepPharmaceuticalRegulationUSA

Allergan reports strong 2nd-qtr figures but still plan to cut 1,500 jobs worldwide

Allergan reports strong 2nd-qtr figures but still plan to cut 1,500 jobs worldwide

21-07-2014

Botox maker Allergan has reported its second quarter operating results while also announcing that it…

AllerganAllerganBotoxFinancialPharmaceuticalUSA

Expensive new hepatitis C drugs are worth the investment

Expensive new hepatitis C drugs are worth the investment

21-07-2014

The debate over the high price of new Hepatitis C Virus (HCV) drugs has focused on the price per pill,…

Anti-viralsCVS CaremarkGilead SciencesHepatitis CPharmaceuticalPricingSovaldiUSA

US breakthrough status for InterMune’s pirfenidone

US breakthrough status for InterMune’s pirfenidone

21-07-2014

US biotech firm InterMune’s Esbriet (pirfenidone) has been granted Breakthrough Therapy designation…

BiotechnologyEsbrietFood and Drug AdministrationInterMunepirfenidoneRare diseasesRegulationRespiratory and PulmonaryUSA

The price of NOT curing hepatitis C - by Robert Zirkelbach

The price of NOT curing hepatitis C - by Robert Zirkelbach

20-07-2014

Over the past few months, there has been increased focus on the price of a new cure for hepatitis C,…

Anti-viralsBiotechnologyFinancialHealthcareHepatitis CHepatitis CLiver transplantsMedicineTradeUSA

1 to 25 of 596 results

Back to top